MGMT and neoplasm: Overall, advanced tumor stage (97%), metastatic disease (100%), moderately to poorly differentiated tumors (84%) and presence of lymphatic invasion (92%) were more frequently observed in tumors with mutated Kras (codon 12) and methylated RASSF1A, FHIT and MGMT genes.